Showing 10 posts of 10 posts found.

NICE recommends Bayer’s Stivarga for advanced hepatocellular carcinoma

November 29, 2018
Sales and Marketing Bayer, NICE, Stivarga, UK, pharma

The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on …

NICE gives final draft guidance on two key cancer drugs

October 12, 2017
Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …


FDA approves first new drug for liver cancer in decade

April 28, 2017
Medical Communications, Sales and Marketing Bayer, Stivarga, hepatocellular carcinoma, liver cancer

The FDA has announced that it has approved the first new treatment for hepatocellular carcinoma (HCC), a type of liver …


Bayer says its Stivarga improved overall survival in liver cancer in late-stage trials

June 30, 2016
Research and Development, Sales and Marketing Bayer, Stivarga, drug trial, liver cancer

German pharma and crop sciences giant Bayer (ETR: BAYN) said late-stage trials for its drug to treat liver cancer showed a …

Bayer’s liver cancer drug meets primary endpoint in late stage trial

May 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial

Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …

Keytruda image

Merck and Eisai partner on cancer therapy trial

March 6, 2015
Research and Development, Sales and Marketing Bayer, Cancer, FDA, Halaven, Lenvima, Merck, Stivarga, keytruda, oncology, pd1

Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …

Bayer image

New drugs give Bayer record sales

February 26, 2015
Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo

Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …

Baye image

Xarelto lift for Bayer

March 3, 2014
Manufacturing and Production, Sales and Marketing Bayer, Eylea, Stivarga, Xarelto, blood thinner, xofigo

Bayer Group says sales of its blood thinner Xarelto will be higher than it had predicted, with peak annual sales …

Zaltrap image

Sanofi’s Zaltrap data published

October 8, 2012
Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin

Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …

FDA approves Bayer’s Stivarga

October 1, 2012
Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin

The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …

Latest content